Piperazine compound as PAF-antagonist
US4940709A · kind A · utility
52Cited by
9References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 1987 |
| Grant date | Jul 10, 1990 |
| Priority date | — |
| Expiry date | Nov 20, 2007 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Diseases caused by platelet activating factor are prevented and treated by administration to a subject of a therapeutically effective amount of a piperazine compound of the formula: ##STR1## wherein R.sup.1 to R.sup.4 are as defined in the specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.